Clinical trial NCT05538624: A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary
Official title: A Phase 1/2 Open-Label, Multicenter, Dose Escalation and Expansion Study of AVB-001, an Intraperitoneally Administered, Cell-Generated, Human IL-2 Immunotherapy in Patients With Platinum-Resistant, High-Grade, Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
PHASE2
Conditions: Neoplasm, Ovarian
Fallopian Tube Cancer
Primary Peritoneal Cavity Cancer
Adenocarcinoma Ovary
Serous Adenocarcinoma of Ovary
Serous Adenocarcinoma of Primary Peritoneum
Primary Peritoneal Carcinoma
High Grade Serous Adenocarcinoma
Keywords: Ovarian Cancer
Primary Peritoneum Cancer
Fallopian Tube Cancer
Immunotherapy
IL-2 Immunotherapy
Metastatic Cancer
Human Interleukin 2
Interleukin 2
IL-2
Encapsulated Cell Therapy
Lead sponsor: Avenge Bio, Inc
Sponsor class: INDUSTRY
First posted: 2022-09-14
Enrollment: 14
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SEQUENTIAL
Intervention model description: In this two-part study, Part 1 is the Dose Escalation Phase; Part 2 is the Dose Expansion Phase.
Primary purpose: TREATMENT

Brief summary: This is an open-label, First-in-Human, Phase 1/2, multicenter study to evaluate the safety and efficacy of a single dose of AVB-001. AVB-001 is an encapsulated cell product engineered to produce native human interleukin-2 (hIL-2). It is delivered intraperitoneally (IP) to patients with high grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube.

Detailed description: This is an open-label, First-in-Human, Phase 1/2, multicenter study to evaluate the safety and efficacy of a single dose of AVB-001. AVB-001 is an encapsulated cell product engineered to produce native human interleukin-2 (IL-2). It is delivered intraperitoneally (IP) to patients with high grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube.

The study will be conducted in two parts. Part 1 is the Dose Escalation Phase using a Bayesian optimal interval (BOIN) model-assisted design in which a single dose of 1 of 4 dose levels of AVB-001 will be administered intraperitoneally (IP) in up to 24 patients. The four ascending dose levels of AVB-001 are targeted to produce hIL-2 levels of 0.6, 1.2, 2.4, and 3.6 μg hIL-2/kg/day. The purpose of Part 1 is to determine the maximally tolerated dose (MTD)/recommended Phase 2 dose (RP2D) level.

Part 2 is the Dose Expansion Phase 2 in which a single dose of AVB-001 at the RP2D will be administered in up to 20 additional adult patients with platinum-resistant, high-grade, serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube. Additional expansion cohorts may be opened in Part 2 either as monotherapy or as an exploratory combination strategy.

Eligibility criteria: Inclusion Criteria:

1. Have histologically confirmed, metastatic or unresectable, platinum-resistant, high-grade, serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube;

   Note: For the purposes of this study, platinum-resistant is defined as a patient who has received platinum-containing chemotherapy and either has platinum-refractory disease (progressed during initial platinum-based chemotherapy) or resistant disease (relapsed within 6 months of initial platinum-containing chemotherapy) or, if previously with platinum-sensitive disease, has received at least 2 lines of platinum-containing chemotherapy and progressed.

   Note: A pathology report confirming histology will be required for enrollment.
2. Have not received more than 5 lines of prior therapy;
3. May have received poly adenosine diphosphate-ribose polymerase (PARP) inhibitors, bevacizumab (or any other antiangiogenic agent), immunotherapy, or cell therapies. (Patients with germline or somatic breast cancer gene (BRCA) mutations must have progressed or been intolerant to PARP inhibitor therapy);
4. Have an Eastern Cooperative Oncology Group performance status 0 to 1 at Screening;
5. Meet the following laboratory criteria:

   * Absolute neutrophil count \>1500/μl;
   * Hemoglobin level ≥9.0 g/dL (transfusion allowed);
   * Platelet count ≥100,000/μl;
   * Creatinine clearance ≥50 mL/minute, measured using the Cockcroft-Gault formula, and serum creatinine ≤1.5 upper limit of normal (ULN);
   * Alanine aminotransferase (ALT) ≤2.5× ULN, aspartate aminotransferase (AST) ≤2.5×ULN; and total bilirubin ≤1.5×ULN (or ≤3×ULN in cases of Gilbert's syndrome); and
   * International normalized ratio \<1.5 and activated partial thromboplastin time (or partial thromboplastin time) within normal limits per the institution.

   Note: Patients on direct-acting anticoagulants or other anticoagulation medications are eligible as long as they are able to hold the drug for the laparoscopic procedure on Day 1 per institutional guidance.
6. Have evidence of measurable disease on computed tomography (CT) or magnetic resonance imaging (MRI) scan as defined by RECIST v1.1;

   Note: Measurable disease cannot include a lesion that was biopsied. Patients must, at a minimum, have 1 measurable lesion.

   Note: Patients with IP disease who also have disease involving the pleural cavity or distant metastases will be eligible if they have measurable or evaluable disease in the IP cavity.
7. Are willing and able to provide written informed consent or have a legally authorized representative willing and able to provide informed consent at Screening.

Exclusion Criteria:

1. Have low-grade serous, mucinous, clear cell, or endometrioid adenocarcinoma of the ovary, primary peritoneum, or fallopian tube; carcinosarcoma; or a mixed histology tumor;
2. Have another malignancy or have had a prior malignancy within 3 years prior to the first dose of study drug or any evidence of residual disease from a previously diagnosed malignancy, excluding adequately managed with curative-intent treatment for basal cell carcinoma, squamous cell carcinoma of the skin, cervical intraepithelial neoplasia, cervical carcinoma in situ, melanoma in situ, or ductal carcinoma in situ of the breast;
3. Have a known or suspected allergy to AVB-001 or known or suspected allergy to any components of AVB-001, including alginate or seaweed;
4. Have any condition that, in the opinion of the Investigator, would lead to the inability of the patient to comply with the Protocol.

Primary outcomes:
measure: Incidence of dose limiting toxicities (DLTs) of IP administered AVB-001 to determine the MTD and RP2D in the Dose Escalation Phase (Part 1)
timeFrame: 4 weeks
measure: Incidence of treatment-emergent adverse events (AEs) and serious AEs (SAEs) of IP administered AVB-001 in the Dose Escalation Phase (Part 1)
timeFrame: 1 year
measure: Investigator-assessed objective response rate (ORR) per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 of IP administered AVB-001 in the Dose Expansion Phase (Part 2)
timeFrame: 1 year
Secondary outcomes:
measure: Investigator-assessed ORR per RECIST v1.1 of IP administered AVB-001 in the Dose Escalation Phase (Part 1)
timeFrame: 1 year
measure: Investigator-assessed ORR per the modified RECIST guideline for immunotherapy (iRECIST) of IP administered AVB-001 in the Dose Escalation Phase (Part 1)
timeFrame: 1 year
measure: Duration of response (DOR) in the Dose Escalation Phase (Part 1)
timeFrame: 1 year
measure: Progression Free Survival (PFS) in the Dose Escalation Phase (Part 1)
timeFrame: 1 year
measure: Overall survival (OS) in the Dose Escalation Phase (Part 1)
timeFrame: 1 year
measure: Concentrations of hIL-2 in blood and ascites/IP fluid during the Dose Escalation Phase (Part 1)
timeFrame: 1 year
measure: Incidence of treatment-emergent AEs and SAEs of IP administered AVB-001 in the Dose Expansion Phase (Part 2)
timeFrame: 1 year
measure: Investigator-assessed ORR per iRECIST of IP administered AVB-001 in the Dose Expansion Phase (Part 2)
timeFrame: 1 year
measure: DOR in the Dose Expansion Phase (Part 2)
timeFrame: 1 year
measure: PFS in the Dose Expansion Phase (Part 2)
timeFrame: 1 year
measure: OS in the Dose Expansion Phase (Part 2)
timeFrame: 1 year
measure: Concentrations of hIL-2 in blood and ascites/IP fluid during the Dose Expansion Phase (Part 2)
timeFrame: 1 year
Other outcomes:
measure: Immunologic changes in peripheral blood and IP environments in the Dose Escalation and Dose Expansion Phases (Parts 1 and 2)
timeFrame: 1 year (Part 1); 1 year (Part 2)
measure: Analysis of anti-drug antibodies (ADA) to AVB-001 in human serum in the Dose Escalation and Dose Expansion Phases (Parts 1 and 2)
timeFrame: 1 year (Part 1); 1 year (Part 2)
Locations:
city: Bethesda
country: United States
facility: National Cancer Institute
state: Maryland
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
city: Pittsburgh
country: United States
facility: UPMC Magee-Womens Hospital
state: Pennsylvania
city: Providence
country: United States
facility: Women & Infants Hospital of Rhode Island
state: Rhode Island
city: Houston
country: United States
facility: MD Anderson Cancer Center
state: Texas
Study officials:
References: